Prognostic factors for upper urinary tract urothelial carcinoma

Nature Reviews Urology

Volumn 8, Issue 8, 2011, Pages 440-447

  Chromecki, Thomas F ^a   Bensalah, Karim ^b   Remzi, Mesut ^c   Verhoest, Grégory ^b   Cha, Eugene K ^d   Scherr, Douglas S ^d   Novara, Giacomo ^e   Karakiewicz, Pierre I ^f   Shariat, Shahrokh F ^d  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b RENNES UNIVERSITY HOSPITAL   (France)

^c Landeskrankenhaus Weinviertel Korneuburg ^*  (Austria)

^d NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^e UNIVERSITY OF PADOVA   (Italy)

^f CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD24 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN;

AGE; ANTIGEN EXPRESSION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER INVASION; CANCER LOCALIZATION; CANCER MORTALITY; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CARCINOMA IN SITU; CLINICAL DECISION MAKING; DECISION SUPPORT SYSTEM; DISEASE SEVERITY; ETHNICITY; HUMAN; HYDRONEPHROSIS; LEUKOCYTE COUNT; LYMPH VESSEL; MICROSATELLITE INSTABILITY; NEPHROURETERECTOMY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TISSUE STRUCTURE; TRANSITIONAL CELL CARCINOMA; TUMOR NECROSIS; UPPER URINARY TRACT UROTHELIAL CARCINOMA; URINE CYTOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; KIDNEY NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 80051705005     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2011.96     Document Type: Review

References (95)

1. Jemal, A., Siegel, R., Xu, J. & Ward, E. Cancer statistics, 2010. CA Cancer J. Clin. 60, 277-300 (2010).
2. Margulis, V. et al. Preoperative multivariable prognostic model for prediction of nonorgan confined urothelial carcinoma of the upper urinary tract. J. Urol. 184, 453-458 (2010).
3. Rouprêt, M. et al. European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. Eur. Urol. 59, 584-594 (2011).
4. Shariat, S. F. et al. Multiple biomarker s improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer 112, 315-325 (2008).
5. Shariat, S. F. et al. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J. Urol. 183, 68-75 (2010).
6. Lughezzani, G. et al. Gender-related differences in patients with stage I to III upper tract urothelial carcinoma: results from the Surveillance, Epidemiology, and End Results database. Urology 75, 321-327 (2010).
7. Fernández, M. I. et al. Evidence-based sex-related outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: results of large multicenter study. Urology 73, 142-146 (2009).
8. Shariat, S. F. et al. Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma. World J. Urol. doi:10.1007/s00345-010- 0594-7.
9. Svatek, R. A. et al. Evidence-based gender related outcomes after radical cystectomy: results of a large multicenter study [abstract 1744]. J. Urol. 181, 629 (2009).
10. Jeldres, C. et al. Gender is an important predictor of cancer-specific survival in patient with transitional cell carcinoma after radical cystectomy [abstract 1761]. J. Urol. 181, 635 (2009).
11. Shariat, S. F. et al. Advanced patient age is associated with inferior cancer-specific survival after radical nephroureterectomy. BJU Int. 105, 1672-1677 (2010).
12. Chromecki, T. F. et al. Chronological age is not an independent predictor of clinical outcomes after radical nephroureterectomy. World J. Urol. doi:10.1007/s00345-011-0677-0.
13. Matsumoto, K. et al. Racial differences in the outcome of patients with urothelial carcinoma of the upper urinary tract: an international study BJU Int. doi:10.1111/j.1464-410X.2011.10188.x.
14. Oosterlinck, W. et al. EAU guidelines on diagnosis and treatment of upper urinary tract transitional cell carcinoma. Eur. Urol. 46, 147-154 (2004). (Pubitemid 38902728)
15. Hall, M. C. et al. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 52, 594-601 (1998).
16. Raman, J. D. et al. Does preoperative symptom classification impact prognosis in patients with clinically localized upper-tract urothelial carcinoma managed by radical nephroureterectomy? Urol. Oncol. doi:10.1016/j.urolonc.2009. 11.007.
17. Brien, J. C. et al. Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. J. Urol. 184, 69-73 (2010).
18. Stimson, C. J. et al. Preoperative hydronephrosis predicts extravesical and node positive disease in patients undergoing cystectomy for bladder cancer. J. Urol. 183, 1732-1737 (2010).
19. Cho, K. S., Hong, S. J., Cho, N. H. & Choi, Y. D. Grade of hydronephrosis and tumor diameter as preoperative prognostic factors in ureteral transitional cell carcinoma. Urology 70, 662-666 (2007). (Pubitemid 350030240)
20. Ng, C. K. et al. Does the presence of hydronephrosis on preoperative axial CT imaging predict worse outcomes for patients undergoing nephroureterectomy for upper-tract urothelial carcinoma? Urol. Oncol. 29, 27-32 (2011).
21. Gore, J. L. et al. Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a Surveillance, Epidemiology, and End Results-Medicare analysis. Cancer 115, 988-996 (2009).
22. Nielsen, M. E. et al. A delay in radical cystectomy of <3 months is not associated with a worse clinical outcome. BJU Int. 100, 1015-1020 (2007). (Pubitemid 47537661)
23. Waldert, M. et al. A delay in radical nephroureterectomy can lead to upstaging. BJU Int. 105, 812-817 (2010).
24. Margulis, V. et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 115, 1224-1233 (2009).
25. Scher, H. et al. NCCN urothelial cancer practice guidelines. National Comprehensive Cancer Network. Oncology (Williston Park) 12, 225-271 (1998). (Pubitemid 28381164)
26. Capitanio, U. et al. Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases. Eur. Urol. 56, 1-9 (2009).
27. Favaretto, R. L. et al. Comparison between laparoscopic and open radical nephroureterectomy in a contemporary group of patients: are recurrence and disease-specific survival associated with surgical technique? Eur. rol. 58, 645-651 (2010).
28. Kamihira, O. et al. Laparoscopic radical nephroureterectomy: a multicenter analysis in Japan. Eur. Urol. 55, 1397-1407 (2009).
29. Rouprêt, M. et al. Oncologic control after open or laparoscopic nephroureterectomy for upper urinary tract transitional cell carcinoma: a single center experience. Urology 69, 656-661 (2007). (Pubitemid 46584731)
30. Favaretto, R. L. et al. The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. Eur. Urol. 58, 574-580 (2010).
31. Isbarn, H. et al. Location of the primary tumor is not an independent predictor of cancer specific mortality in patients with upper urinary tract urothelial carcinoma. J. Urol. 182, 2177-2181 (2009).
32. Raman, J. D. et al. Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. Eur. Urol. 57, 1072-1079 (2010).
33. Langner, C. et al. pT classification, grade, and vascular invasion as prognostic indicators in urothelial carcinoma of the upper urinary tract. Mod. Pathol. 19, 272-279 (2006). (Pubitemid 43117612)
34. Novara, G. et al. Independent predictors of cancer-specific survival in transitional cell carcinoma of the upper urinary tract: multi-institutional dataset from 3 European centers. Cancer 110, 1715-1722 (2007). (Pubitemid 47557295)
35. Novara, G. et al. Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study. Eur. Urol. 57, 1064-1071 (2010).
36. Lopez-Beltran, A., Bassi, P., Pavone-Macaluso, M. & Montironi, R. Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis. Eur. Urol. 45, 257-266 (2004). (Pubitemid 38221396)
37. Bolenz, C. et al. Risk stratification of patients with nodal involvement in upper tract urothelial carcinoma: value of lymph-node density. BJU Int. 103, 302-306 (2009).
38. Mullerad, M. et al. Bladder cancer as a prognostic factor for upper tract transitional cell carcinoma. J. Urol. 172, 2177-2181 (2004). (Pubitemid 39507486)
39. Lehmann, J. et al. Transitional cell carcinoma of the ureter: prognostic factors influencing progression and survival. Eur. Urol. 51, 1281-1288 (2007). (Pubitemid 46436299)
40. Li, W. M. et al. The prognostic predictors of primary ureteral transitional cell carcinoma after radical nephroureterectomy. J. Urol. 182, 451-458 (2009).
41. Li, C. C. et al. Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients. Eur. Urol. 54, 1127-1134 (2008).
42. Remzi, M. et al. Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients. BJU Int. 103, 307-311 (2009).
43. Chade, D. C. et al. Clinical outcome of primary versus secondary bladder carcinoma in situ. J. Urol. 184, 464-469 (2010).
44. Shariat, S. F. et al. Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy. Eur. Urol. 51, 152-160 (2007). (Pubitemid 44821530)
45. Pieras, E. et al. Concomitant carcinoma in situ and tumour size are prognostic factors for bladder recurrence after nephroureterectomy for upper tract transitional cell carcinoma. BJU Int. 106, 1319-1323 (2010).
46. Wheat, J. C. et al. Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy. Urol. Oncol. doi:10.1016/j.urolonc.2010. 01.001.
47. Otto, W. et al. Concomitant carcinoma in situ as an independent prognostic parameter for recurrence and survival in upper tract urothelial carcinoma: a multicenter analysis of 772 patients. World J. Urol. doi:10.1007/s00345-011-0645-8.
48. Langner, C. et al. Tumor necrosis as prognostic indicator in transitional cell carcinoma of the upper urinary tract. J. Urol. 176, 910-913 (2006).
49. Zigeuner, R. et al. Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. Eur. Urol. 57, 575-581 (2010).
50. Seitz, C. et al. Association of tumor necrosis with pathological features and clinical outcome in 754 patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma: an international validation study. J. Urol. 184, 1895-1900 (2010).
51. Hong, B. et al. Prognostic value of lymphovascular invasion in transitional cell carcinoma of upper urinary tract. Urology 65, 692-696 (2005). (Pubitemid 40523001)
52. Kim, D. S. et al. Lymphovascular invasion and pT stage are prognostic factors in patients treated with radical nephroureterectomy for localized upper urinary tract transitional cell carcinoma. Urology 75, 328-332 (2010).
53. Saito, K. et al. Lymphovascular invasion is independently associated with poor prognosis in patients with localized upper urinary tract urothelial carcinoma treated surgically. J. Urol. 178, 2291-2296 (2007). (Pubitemid 350052165)
54. Bolenz, C. et al. Lymphangiogenesis occurs in upper tract urothelial carcinoma and correlates with lymphatic tumour dissemination and poor prognosis. BJU Int. 103, 1040-1046 (2009).
55. Chung, S. D. et al. Lymphovascular invasion predicts poor outcome of urothelial carcinoma of renal pelvis after nephroureterectomy. BJU Int. 103, 1047-1051 (2009).
56. Kikuchi, E. et al. Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. J. Clin. Oncol. 27, 612-618 (2009).
57. Margulis, V., Lotan, Y., Montorsi, F. & Shariat, S. F. Predicting survival after radical cystectomy for bladder cancer. BJU Int. 102, 15-22 (2008). (Pubitemid 351799452)
58. Simone, G. et al. Independent prognostic value of tumour diameter and tumour necrosis in upper urinary tract urothelial carcinoma. BJU Int. 103, 1052-1057 (2009).
59. Langner, C., Hutterer, G., Chromecki, T., Rehak, P. & Zigeuner, R. Patterns of invasion and histological growth as prognostic indicators in urothelial carcinoma of the upper urinary tract. Virchows Arch. 448, 604-611 (2006). (Pubitemid 44490558)
60. Fritsche, H. M. et al. Macroscopic sessile tumor architecture is a pathologic feature of biologically aggressive upper tract urothelial carcinoma. Urol. Oncol. doi:10.1016/j.urolonc.2010.07.010.
61. Fromont, G. et al. Tissue microarray analysis of the prognostic value of E-cadherin, Ki67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma. Eur. Urol. 48, 764-770 (2005). (Pubitemid 41495375)
62. Winkler, A. et al. CD24 expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression. Virchows Arch. 450, 59-64 (2007). (Pubitemid 46360738)
63. Nakanishi, K. et al. Expression of hypoxia-inducible factor-1alpha protein predicts survival in patients with transitional cell carcinoma of the upper urinary tract. Clin. Cancer Res. 11, 2583-2590 (2005). (Pubitemid 40569457)
64. Kamai, T. et al. Prognostic significance of p27Kip1 and Ki-67 expression in carcinoma of the renal pelvis and ureter. BJU Int. 86, 14-19 (2000). (Pubitemid 30420757)
65. Barbieri, C. E. et al. Tissue-based molecular markers for bladder cancer. Minerva Urol. Nefrol. 62, 241-258 (2010).
66. Zigeuner, R. et al. Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma. Urology 63, 1079-1083 (2004). (Pubitemid 38746807)
67. Nakanishi, K. et al. Expression of bcl-2 oncoprotein in transitional cell carcinoma of the upper urinary tract. Virchows Arch. 432, 445-450 (1998). (Pubitemid 28266201)
68. Nakanishi, K. et al. Expression of survivin does not predict survival in patients with transitional cell carcinoma of the upper urinary tract. Virchows Arch. 441, 559-563 (2002). (Pubitemid 35435825)
69. Nakanishi, K. et al. Expression of telomerase mRNA component (hTR) in transitional cell carcinoma of the upper urinary tract. Cancer 86, 2109-2116 (1999).
70. Leibl, S. et al. EGFR expression in urothelial carcinoma of the upper urinary tract is associated with disease progression and metaplastic morphology. APMIS 116, 27-32 (2008). (Pubitemid 351191103)
71. Youssef, R. F. et al. Prognostic effect of urinary bladder carcinoma in situ on clinical outcome of subsequent upper tract urothelial carcinoma. Urology 77, 861-866 (2010).
72. Eltz, S., Comperat, E., Cussenot, O. & Rouprêt, M. Molecular and histological markers in urothelial carcinomas of the upper urinary tract. BJU Int. 102, 532-535 (2008).
73. Akkad, T. et al. Fluorescence in situ hybridization for detecting upper urinary tract tumors-a preliminary report. Urology 70, 753-757 (2007). (Pubitemid 350030237)
74. Luo, B. et al. Utility of fluorescence in situ hybridization in the diagnosis of upper urinary tract urothelial carcinoma. Cancer Genet. Cytogenet. 189, 93-97 (2009).
75. Mian, C. et al. Fluorescence in situ hybridisation in the diagnosis of upper urinary tract tumours. Eur. Urol. 58, 288-292 (2010).
76. Herman, M. P., Svatek, R. S., Lotan, Y., Karakiewicz, P. I. & Shariat, S. F. Urine-based biomarkers for the early detection and surveillance of non-muscle invasive bladder cancer. Minerva Urol. Nefrol. 60, 217-235 (2008).
77. Nieder, A. M., Soloway, M. S. & Herr, H. W. Should we abandon the FISH test? Eur. Urol. 51, 1469-1471 (2007). (Pubitemid 46634755)
78. Chen, A. A. & Grasso, M. Is there a role for FISH in the management and surveillance of patients with upper tract transitional-cell carcinoma? J. Endourol. 22, 1371-1374 (2008). (Pubitemid 351913508)
79. Johannes, J. R., Nelson, E., Bibbo, M. & Bagley, D. H. Voided urine fluorescence in situ hybridization testing for upper tract urothelial carcinoma surveillance. J. Urol. 184, 879-882 (2010).
80. Rouprêt, M. et al. Microsatellite instability as indicator of MSH2 gene mutation in patients with upper urinary tract transitional cell carcinoma. J. Med. Genet. 41, e91 (2004).
81. Acher, P., Kiela, G., Thomas, K. & O'Brien, T. Towards a rational strategy for the surveillance of patients with Lynch syndrome (hereditary non-polyposis colon cancer) for upper tract transitional cell carcinoma. BJU Int. 106, 300-302 (2010).
82. Rouprêt, M., Yates, D. R., Comperat, E. & Cussenot, O. Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (lynch syndrome) tumor spectrum. Eur. Urol. 54, 1226-1236 (2008).
83. Rouprêt, M. et al. Checkup and management of upper urinary tract tumours in 2010: An update from the committee of cancer from the French National Association of Urology [French]. Prog. Urol. 20, 260-271 (2010).
84. Rouprêt, M., Azzouzi, A. R. & Cussenot, O. Microsatellite instability and transitional cell carcinoma of the upper urinary tract. BJU Int. 96, 489-492 (2005). (Pubitemid 41224314)
85. Saito, K. et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically. BJU Int. 100, 269-273 (2007) (Pubitemid 47036572)
86. Elstein, A. S. Heuristics and biases: selected errors in clinical reasoning. Acad. Med. 74, 791-794 (1999). (Pubitemid 29344140)
87. Vlaev, I. & Chater, N. Game relativity: how context influences strategic decision making. J. Exp. Psychol. Learn. Mem. Cogn. 32, 131-149 (2006). (Pubitemid 43283752)
88. Hogarth, R. M. & Karelaia, N. Heuristic and linear models of judgment: matching rules and environments. Psychol. Rev. 114, 733-758 (2007).
89. Ross, P. L. et al. Comparisons of nomograms and urologists' predictions in prostate cancer. Semin. Urol. Oncol. 20, 82-88 (2002). (Pubitemid 34522545)
90. Ross, P. L., Scardino, P. T. & Kattan, M. W. A catalog of prostate cancer nomograms. J. Urol. 165, 1562-1568 (2001). (Pubitemid 32410239)
91. Specht, M. C., Kattan, M. W., Gonen, M., Fey, J. & Van Zee, K. J. Predicting nonsentinel node status after positive sentinel lymph biopsy for breast cancer: clinicians versus nomogram. Ann. Surg. Oncol. 12, 654-659 (2005). (Pubitemid 41126095)
92. Walz, J. et al. Clinicians are poor raters of life-expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer. BJU Int. 100, 1254-1258 (2007). (Pubitemid 350043902)
93. Shariat, S. F., Capitanio, U., Jeldres, C. & Karakiewicz, P. I. Can nomograms be superior to other prediction tools? BJU Int. 103, 492-495 (2009).
94. Shariat, S. F., Karakiewicz, P. I., Suardi, N. & Kattan, M. W. Comparison of nomograms with other methods for predicting outcomes in prostate cancer: a critical analysis of the literature. Clin. Cancer Res. 14, 4400-4407 (2008).
95. Bensalah, K., Montorsi, F. & Shariat, S. F. Challenges of cancer biomarker profiling. Eur. Urol. 52, 1601-1609 (2007). (Pubitemid 350052431)